Studying antithyroglobulin antibodies in hashimotos disease with murphy repertory
Not Applicable
- Conditions
- Health Condition 1: E063- Autoimmune thyroiditis
- Registration Number
- CTRI/2024/03/063729
- Lead Sponsor
- il
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients suffering from Hashimoto’s thyroiditis with elevated TSH, anti-Thyroglobulin Ab.
Female patients will be included.
Patients between 18-60 years of age.
Exclusion Criteria
Pregnant, post-partum and nursing women will be excluded.
Known cases of other autoimmune disorders.
Known cases of thyroid malignancy.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The efficacy of Homoeopathic medicines in reducing the Anti-thyroglobulin antibody level in Hashimoto’s thyroiditis will be proved before and after an interval of 6 months of the treatment. <br/ ><br>Cases will be evaluated for age, sex, occupation, symptoms presented, values of anti-thyroglobulin antibody (anti-Tg), thyroid peroxidase antibodies and TSH will be considered for statistical analysis and to derive the result, thereby validating the study.Timepoint: The efficacy of Homoeopathic medicines in reducing the Anti-thyroglobulin antibody level in Hashimoto’s thyroiditis will be proved before and after an interval of 6 months of the treatment. <br/ ><br>Cases will be evaluated for age, sex, occupation, symptoms presented, values of anti-thyroglobulin antibody (anti-Tg), thyroid peroxidase antibodies and TSH will be considered for statistical analysis and to derive the result, thereby validating the study.
- Secondary Outcome Measures
Name Time Method The symptomatic improvement of the patient with hypothyroidism assessed by Zulewski clinical score will reveal the efficacy of Murphy repertory in the treatment of Hashimoto’s thyroiditis. <br/ ><br>An alphabetical repertory will be constructed on thyroid disorders.Timepoint: Medicines given will be observed for 2 weeks consecutively for 6 months